Stockscreener 앱 받기
4.60
1.77%
0.08
시간 외 거래:
4.51
-0.09
-1.96%
Alto Neuroscience Inc 주식(ANRO)의 최신 뉴스
FY2024 EPS Estimate for Alto Neuroscience Boosted by Analyst - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Wedbush Equities Analysts Reduce Earnings Estimates for ANRO - MarketBeat
RA Capital Management Reduces Stake in Alto Neuroscience Inc - GuruFocus.com
Stifel Nicolaus Has Lowered Expectations for Alto Neuroscience (NYSE:ANRO) Stock Price - MarketBeat
FMR LLC Acquires Shares in Alto Neuroscience Inc - GuruFocus.com
Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Yahoo Finance
Latest Company News - Investing.com
Largest borrow rate increases among liquid names - TipRanks
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire
Alto Neuroscience to Participate in Upcoming Investor Conferences - StockTitan
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm - PR Newswire
ANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Reach Out - AccessWire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Connect - AccessWire
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Learn More About the Investigation - AccessWire
Alto Neuroscience, Inc. (ANRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Alto Neuroscience, Linkage Global, Pixie Dust: Top 3 Stocks With Explosive Retail Follower Growth Last Week - Barchart
Alto Neuroscience, Inc. (NYSE:ANRO) Short Interest Up 29.9% in October - MarketBeat
Q1 EPS Estimates for Alto Neuroscience Lowered by Wedbush - MarketBeat
Alto Neuroscience stock crashes amid failed study and Wedbush downgrade - MSN
William Blair Has Negative Outlook for ANRO FY2028 Earnings - MarketBeat
Alto Neuroscience’s depression drug trial fails at phase 2 - BioPharma-Reporter.com
Alto Neuroscience sinks as ALTO-100 misses goal in MDD - The Pharma Letter
Wedbush downgrades Alto Neuroscience to Neutral following ALTO-100 readout - Yahoo Finance
RODMAN&RENSHAW Lowers Alto Neuroscience (NYSE:ANRO) to Hold - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Alto Neuroscience’s Depression Trial Failure Sends Shares Into Downward Spiral - MedCity News
Alto depression drug failure sends shares plunging 66% - Green Market Report
Gold Moves Lower; AT&T Earnings Top Views - MSN
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform - Yahoo Finance
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
2024-10-23 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Alto Neuroscience, Inc. (ANRO) And Encourages Stockholders to Connect | NYSE:ANRO | Press Release - Stockhouse Publishing
Alto Neuroscience stock downgraded by Rodman & Renshaw on trial miss, PT slashed - Investing.com
Alto Neuroscience stock crashes amid failed study and Wedbush downgrade (NYSE:ANRO) - Seeking Alpha
Alto Hits The Wrong Note In Depression - Scrip
Alto Neuroscience Target of Unusually High Options Trading (NYSE:ANRO) - MarketBeat
Alto Neuroscience shares PT slashed by Baird following ALTO-100 failure - Investing.com
Alto Neuroscience Stock Plummets Pre-Market After MDD Drug Trial Misses Primary Endpoint, Grabs Retail Attention - Barchart
Robert W. Baird Lowers Alto Neuroscience (NYSE:ANRO) Price Target to $10.00 - MarketBeat
Alto hits new low as depression drug flunks key test - Yahoo Finance
Alto’s Phase IIb study of ALTO-100 for MDD fails to meet primary endpoint - Clinical Trials Arena
Alto Neuroscience (NYSE:ANRO) Downgraded to "Neutral" at Wedbush - MarketBeat
Alto Depression Therapy Fails Mid-Stage Trial, 9 Months After IPO - BioSpace
Alto Neuroscience reports setback in depression drug trial By Investing.com - Investing.com Canada
Alto Neuroscience (NYSE:ANRO) Trading 1.6% HigherShould You Buy? - MarketBeat
Alto Neuroscience (NYSE:ANRO) Stock Price Up 1.6% – Here’s What Happened - Defense World
Dow Tumbles Over 250 Points; Boeing Posts Q3 LossBoeing (NYSE:BA) - Benzinga
Alto Neuroscience stock craters 57% post-market on failed study - MSN
Alto Neuroscience’s Phase 2b study of ALTO-100 did not meet primary endpoint - TipRanks
ANROAlto Neuroscience Inc. Latest Stock News & Market Updates - StockTitan
Alto Neuroscience Shares Plunge After ALTO-100 Study Misses Primary Endpoint - MarketWatch
Alto Neuroscience falls 47% after announcing ALTO-100 did not meet endpoint - TipRanks
Alto Neuroscience reports setback in depression drug trial - Investing.com
After-hours movers: McDonald's, Starbucks, Seagate, Alto Neuroscience and more - Investing.com India
3.66%
1.11%
자본화:
|
볼륨(24시간):